interleukin-8 and Bronchial-Diseases

Topics: Airway Obstruction; Asthma; Biomarkers; Bronchial Diseases; Comorbidity; Cross-Sectional Studies; Eosinophilia; Female; Glucocorticoids; Goals; Humans; Interleukin-8; Male; Medication Adherence; Middle Aged; Nebulizers and Vaporizers; Severity of Illness Index; Spain

Since the start of Afghanistan combat operations in 2001, there has been an increase in complaints of respiratory illnesses in deployed soldiers with no previous history of lung disorders. It is postulated that deployment-related respiratory illnesses are the result of inhalation of desert particulate matter (PM) potentially acting in combination with exposure to other pro-inflammatory compounds. Why some, but not all, soldiers develop respiratory diseases remains unclear. Our goal was to investigate if human airway epithelial cells primed with IL-13, a type 2 inflammatory cytokine, demonstrate stronger pro-inflammatory responses to Afghanistan desert PM (APM). Primary human brushed bronchial epithelial cells from non-deployed, healthy subjects were exposed to APM, both with and without IL-13 pretreatment. APM exposure in conjunction with IL-13 resulted in significantly increased expression of IL-8, a pro-inflammatory cytokine involved in neutrophil recruitment and activation. Furthermore, expression of TLR2 mRNA was increased after combined IL-13 and APM exposure. siRNA-mediated TLR2 knockdown dampened IL-8 production after exposure to APM with IL-13. APM with IL-13 treatment increased IRAK-1 (a downstream signaling molecule of TLR2 signaling) activation, while IRAK-1 knockdown effectively eliminated the IL-8 response to APM and IL-13. Our data suggest that APM exposure may promote neutrophilic inflammation in airways with a type 2 cytokine milieu.

Topics: Afghanistan; Aged; Bronchial Diseases; Cells, Cultured; Cytokines; Epithelial Cells; Female; Healthy Volunteers; Humans; Inflammation; Interleukin-1 Receptor-Associated Kinases; Interleukin-13; Interleukin-8; Male; Middle Aged; Particulate Matter; RNA, Small Interfering; Signal Transduction; Toll-Like Receptor 2

Cystic fibrosis (CF) airway epithelia exhibit altered Cl(-) and Na(+) transport properties and increased IL-8 secretion. In the present study, we examined whether a small proportion of cells with a normal phenotype could normalize the ion transport and IL-8 secretion properties of a CF airway epithelial cell layer. We obtained three types of primary cultures of human bronchial epithelial cells: one composed of 100% non-CF cells, one of 100% CF cells, and one of 10% non-CF and 90% CF cells ("cocultures"). Measurement of the bioelectric properties in Ussing chambers revealed that the cocultures displayed Cl(-) and Na(+) transports similar to those observed in the 100% non-CF cultures and significantly different from CF cultures. IL-8 concentration in the coculture supernatant was not different from non-CF cultures, but was significantly lower than in CF cultures. This study provides evidence that 10% bronchial epithelial cells expressing a normal phenotype are sufficient to functionally correct a primary culture of CF bronchial epithelial cells in vitro. We postulate that 10% cells with a non-CF phenotype can be used as a goal for the design of gene therapy and cell therapy trials for CF lung disease.

Topics: Adult; Apoptosis; Bronchial Diseases; Cell Proliferation; Coculture Techniques; Cystic Fibrosis; Epithelial Cells; Genetic Diseases, Inborn; Genetic Therapy; Homozygote; Humans; Interleukin-8; Ions; Male; Phenotype

Interleukin 9 (IL-9) is a cytokine produced by activated T lymphocytes and that activates in vitro mast cells as well as T and B lymphocytes. In vivo, transgenic mice overexpressing the gene encoding IL-9 show several of the hallmarks of human allergic asthma: increased IgE concentration, bronchial mastocytosis, eosinophilia, increased mucus production, as well as bronchial hyperresponsiveness. Whereas some of these features reflect direct IL-9 activities on target cells such as mast cells and B lymphocytes, increased mucus production and eosinophilia rather result from IL-13 and IL-5 production induced by IL-9 in T lymphocytes and mast cells. Preclinical studies in mice have shown that anti-IL-9 blocking antibodies interfere with the development of asthma-like reactions. In the human species, asthmatic patients produce large amounts of this cytokine and IL-9 production correlates nicely with species biological parameters of the disease. Phase 2 clinical trials are in progress to test the efficacy of anti-IL-9 antibodies in humans.

Topics: Animals; Asthma; Bronchial Diseases; Bronchial Hyperreactivity; Cells, Cultured; Clinical Trials, Phase II as Topic; Disease Models, Animal; Eosinophilia; Humans; Immunoglobulin E; Interleukin-8; Mast Cells; Mastocytosis; Mice; Mice, Transgenic; T-Lymphocytes

Topics: Bronchial Diseases; Case-Control Studies; Female; Humans; Immunity, Innate; Infant; Infant, Newborn; Interleukin-1beta; Interleukin-6; Interleukin-8; Interleukins; Male; Nasopharynx; Respiratory Syncytial Virus Infections